Upadacitinib Enantiomer Impurity
✓
데이터 정확도 100%
연중무휴 과학적 지원
⬡
제품 품질에 대한 무관용 원칙

재고 위치

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* 재고 가용성에 따라 다름

Documentation

MSDS 다운로드

샘플 COA 다운로드

포함 사항: HPLC, MASS/LC-MS, 1H NMR, FT-IR, 함량, 구조 규명 보고서(SER), 그리고 제품에 따라 추가 분석 데이터가 제공됩니다.

1310726-59-0Upadacitinib Enantiomer Impurity

● 재고 있음

카탈로그 번호:VE0027850
CAS 번호:1310726-59-0
분자식:C17H19F3N6O
분자량:380.38 g/mol

에 대한 추가 정보 CAS 1310726-59-0

모약물

Upadacitinib

IUPAC명

(3R,4S)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

Pharmacopeial Synonyms

N/A

동의어

N/A

SMILES

O=C(N1C[C@H](CC)[C@H](C2=CN=C3C=NC(NC=C4)=C4N32)C1)NCC(F)(F)F

InChI

InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m0/s1

설명

Upadacitinib Enantiomer Impurity (CAS 1310726-59-0) is the chiral counter enantiomer encountered during synthesis and resolution of upadacitinib. Monitoring this enantiomeric impurity is essential to ensure stereochemical purity and compliance with regulatory impurity limits. Analytical characterization commonly employs chiral high-performance liquid chromatography, chiroptical methods, polarimetry, nuclear magnetic resonance and mass spectrometry to determine enantiomeric excess, confirm structure and achieve trace level quantitation. Stability assessment and process development address potential racemization pathways, while control strategies including in-process controls, validated assays and defined specification limits mitigate risk to pharmaceutical quality in line with ICH impurity guidance.

견적 요청

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url